Insulet Corporation
General ticker "PODD" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $17.0B (TTM average)
Insulet Corporation does not follow the US Stock Market performance with the rate: -35.5%.
Estimated limits based on current volatility of 1.5%: low 138.28$, high 142.48$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 5400 (+38.5%) as of 2025
- US accounted for 74.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Product development failure, Intellectual property risks, Manufacturing supply, Regulatory and compliance
- Current price 43.6% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [249.97$, 376.07$]
- 2026-12-31 to 2027-12-31 estimated range: [251.38$, 379.56$]
Financial Metrics affecting the PODD estimates:
- Positive: with PPE of 57.7 at the end of fiscal year the price was neutral
- Positive: 15.80 < Operating profit margin, % of 17.50
- Positive: 2.37 < Operating cash flow per share per price, % of 2.81
- Positive: -51.61 < Industry operating profit margin (median), % of -29.60
- Positive: Industry inventory ratio change (median), % of 0.70 <= 1.15
- Positive: 5.14 < Return on assets ratio (scaled to [-100,100]) of 7.19
- Positive: 42.26 < Shareholder equity ratio, % of 47.49 <= 49.86
- Positive: Inventory ratio change, % of -2.86 <= -1.30
Short-term PODD quotes
Relationship graph
Long-term PODD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,697.10MM | $2,071.60MM | $2,708.10MM |
| Operating Expenses | $1,477.00MM | $1,762.70MM | $2,234.30MM |
| Operating Income | $220.10MM | $308.90MM | $473.80MM |
| Non-Operating Income | $-5.40MM | $-8.70MM | $-134.30MM |
| Interest Expense | $36.20MM | $42.70MM | $59.40MM |
| R&D Expense | $205.00MM | $219.60MM | $301.10MM |
| Income(Loss) | $214.70MM | $300.20MM | $339.50MM |
| Taxes | $8.30MM | $-118.10MM | $92.40MM |
| Net Income(Loss)* | $206.30MM | $418.30MM | $247.10MM |
| Stockholders Equity | $732.70MM | $1,211.60MM | $1,515.20MM |
| Inventory | $402.60MM | $430.40MM | $452.60MM |
| Assets | $2,588.20MM | $3,087.70MM | $3,190.40MM |
| Operating Cash Flow | $145.70MM | $430.30MM | $569.30MM |
| Capital expenditure | $75.60MM | $124.90MM | $191.60MM |
| Investing Cash Flow | $-119.40MM | $-146.20MM | $-222.70MM |
| Financing Cash Flow | $-13.60MM | $-28.10MM | $-595.30MM |
| Earnings Per Share** | $2.96 | $5.97 | $3.51 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.